These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 24891456)
1. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456 [TBL] [Abstract][Full Text] [Related]
2. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007 [TBL] [Abstract][Full Text] [Related]
3. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281 [TBL] [Abstract][Full Text] [Related]
4. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Blanes A; Diaz-Cano SJ Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934 [TBL] [Abstract][Full Text] [Related]
5. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas. Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173 [TBL] [Abstract][Full Text] [Related]
6. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential. Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666 [TBL] [Abstract][Full Text] [Related]
7. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease. de Cremoux P; Rosenberg D; Goussard J; Brémont-Weil C; Tissier F; Tran-Perennou C; Groussin L; Bertagna X; Bertherat J; Raffin-Sanson ML Endocr Relat Cancer; 2008 Jun; 15(2):465-74. PubMed ID: 18508999 [TBL] [Abstract][Full Text] [Related]
8. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380 [TBL] [Abstract][Full Text] [Related]
9. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174 [TBL] [Abstract][Full Text] [Related]
10. Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Barzon L; Pacenti M; Masi G; Stefani AL; Fincati K; Palù G Oncology; 2005; 68(4-6):414-21. PubMed ID: 16020971 [TBL] [Abstract][Full Text] [Related]
11. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516 [TBL] [Abstract][Full Text] [Related]
12. Molecular markers and the pathogenesis of adrenocortical cancer. Soon PS; McDonald KL; Robinson BG; Sidhu SB Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740 [TBL] [Abstract][Full Text] [Related]
13. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045 [TBL] [Abstract][Full Text] [Related]
14. Sonic hedgehog signaling is active in human adrenal cortex development and deregulated in adrenocortical tumors. Gomes DC; Leal LF; Mermejo LM; Scrideli CA; Martinelli CE; Fragoso MC; Latronico AC; Tone LG; Tucci S; Yunes JA; Cardinalli IA; Mastellaro MJ; Brandalise SR; Ramalho F; Moreira AC; Ramalho LN; de Castro M; Antonini SR J Clin Endocrinol Metab; 2014 Jul; 99(7):E1209-16. PubMed ID: 24712566 [TBL] [Abstract][Full Text] [Related]
15. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702 [TBL] [Abstract][Full Text] [Related]